6-Month Multicenter Randomized Open-label 2-Arm Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus? Injected Once Daily in Children and Adolescents age 6 - 17 years with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period EFC13957
-
- STATUS
- Not Recruiting
Summary
The main purpose of this study is to evaluate, in children and adolescents 6 to 17 years old with T1DM, the efficacy and safety of a newly developed formulation of insulin glargine (HOE901-U300) with that of insulin glargine U100, which has been marketed as Lantus.
Description
The main purpose of this study is to evaluate, in children and adolescents 6 to 17 years old with T1DM, the efficacy and safety of a newly developed formulation of insulin glargine (HOE901-U300) with that of insulin glargine U100, which has been marketed as Lantus.
Details
| Condition | type 1 diabetes |
|---|---|
| Age | 6years - 17years |
| Clinical Study Identifier | TX7299 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.